Dynavax Technologies (DVAX)
(Delayed Data from NSDQ)
$11.21 USD
+0.04 (0.36%)
Updated Apr 26, 2024 03:59 PM ET
After-Market: $11.19 -0.02 (-0.18%) 6:54 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Dynavax Technologies Corporation [DVAX]
Reports for Purchase
Showing records 21 - 40 ( 121 total )
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Emergency Use Approval in India for CORBEVAX COVID-19 Vaccine With CpG 1018 Adjuvant; Raising PT to $28
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Dynavax''s Partner Valneva Announces EC Approval of Advance Purchase Agreement For Its COVID-19 Vaccine, VLA2001
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
3Q21 Results; Record Heplisav-B Sales and Increased CpG 1018 Adjuvant FY21 Revenue Guidance
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Positive Phase 3 Data for Valneva''s COVID-19 Vaccine Candidate Adjuvanted With Dynavax''s CpG 1018
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Recap of Dynavax at the Annual Hepatitis B Virus Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Agreement Announced With the DOD to Develop a Recombinant Plague Vaccine Adjuvanted With CpG 1018
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
ACIP Meeting Looks Good for Universal Hepatitis B Vaccination Recommendation
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Positive Data for Clover Biopharmaceuticals'' SCB-2019 COVID-19 Vaccine Adjuvanted With Dynavax''s CpG 1018
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Hepatitis B Vaccines Session Included in the Draft Agenda for ACIP Meeting
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Dynavax''s Partner Valneva Received a Termination Notice for its COVID-19 Vaccine Supply Agreement
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Positive News on Two Fronts; Partner Launch in Taiwan and European Rolling Submission Commences With Another Partner
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
2Q21 Results; The Best Quarter for Heplisav-B So Far; Impressive Adjuvant Sales; Raising PT to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Dynavax Announces Commercial Supply Agreement With Biological E. Limited
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Commercial Supply Agreement With Clover Biopharmaceuticals Announced
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Commercialization Agreement Announced for Heplisav-B in Germany
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
1Q21 Results; Strong CpG 1018 Adjuvant Sales Overshadow Heplisav-B YOY Sales Decline
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Pivotal Phase 3 Trial of Valneva''s COVID-19 Vaccine Candidate Adjuvanted With Dynavax''s CpG 1018 Initiated
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Solid Phase 1/2 Initial Results Reported for VLA2001 Vaccine Candidate Adjuvanted With CpG 1018
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E